Aclaris Therapeutics (ACRS) director receives RSU and option grants, boosts holdings

Rhea-AI Filing Summary

Aclaris Therapeutics director Anand Mehra reported routine equity compensation activity. On June 4, 2026, he received 10,987 restricted stock units and a stock option for 42,350 shares of common stock at an exercise price of $4.71 per share, both granted at no cash cost.

The option vests in twelve equal monthly installments starting on July 4, 2026, while the 10,987 restricted stock units are scheduled to vest on June 4, 2027, subject to his continuous service. On June 5, 2026, 11,580 previously granted restricted stock units vested and were exercised into 11,580 shares of common stock, bringing his direct common stock holdings to 726,403 shares.

Insights

Equity compensation analyst

Director received routine RSU and option grants and saw prior RSUs vest into common shares, with no open-market trades.

The transactions show Anand Mehra, a director of Aclaris Therapeutics, receiving standard non-cash equity awards: 10,987 restricted stock units (RSUs) and stock options for 42,350 shares at an exercise price of $4.71, plus vesting of 11,580 older RSUs into common stock.

These awards are tied to service-based vesting, with the option vesting monthly over a year starting July 4, 2026 and the new RSUs vesting on June 4, 2027. After the June 5 conversion, Mehra directly holds 726,403 common shares, and no shares were bought or sold in the open market.

Insider Trade Summary

11,580 shares exercised/converted

Mixed 4 txns

Insider Mehra Anand

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	11,580	$0.00	--
Exercise	Common Stock	11,580	$0.00	--
Grant/Award	Stock Option (Right to Buy)	42,350	$0.00	--
Grant/Award	Restricted Stock Units	10,987	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 726,403 shares (Direct, null); Stock Option (Right to Buy) — 42,350 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. The shares underlying these restricted stock units vested on June 5, 2026.

Key Figures

RSUs exercised: 11,580 shares Common stock holdings: 726,403 shares New RSU grant: 10,987 units +4 more

7 metrics

RSUs exercised 11,580 shares Restricted stock units vested and converted on June 5, 2026

Common stock holdings 726,403 shares Direct holdings after June 5, 2026 transactions

New RSU grant 10,987 units Restricted stock units granted on June 4, 2026

Stock option grant 42,350 options Stock option (right to buy) granted on June 4, 2026

Option exercise price $4.71 per share Exercise price for 42,350-share stock option grant

Option expiration June 3, 2036 Expiration date of stock option grant

RSU vesting date June 4, 2027 Vesting date for the 10,987 new restricted stock units

Key Terms

Restricted Stock Units, Stock Option (Right to Buy), Continuous Service, non-employee director compensation policy, +1 more

5 terms

Restricted Stock Units financial

"The shares underlying these restricted stock units will vest in one installment on June 4, 2027"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with 42,350.0000 shares at a conversion or exercise price of 4.7100"

Continuous Service financial

"subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan"

non-employee director compensation policy financial

"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy"

Equity Incentive Plan financial

"as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/08/2026 - 04:15 PM Accepted by SEC EDGAR 06/08/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehra Anand

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		M		11,580	A	(1)	726,403	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.71	06/04/2026		A		42,350		(2)	06/03/2036	Common Stock	42,350	$0	42,350(3)	D
Restricted Stock Units	(1)	06/04/2026		A		10,987		(4)	(4)	Common Stock	10,987	$0	10,987(3)	D
Restricted Stock Units	(1)	06/05/2026		M			11,580	(5)	(5)	Common Stock	11,580	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.

3. This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

4. The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.

5. The shares underlying these restricted stock units vested on June 5, 2026.

	/s/ Matthew Rothman, Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Aclaris Therapeutics (ACRS) director Anand Mehra report?

Anand Mehra reported equity compensation events, not market trades. He received 10,987 restricted stock units and 42,350 stock options, and 11,580 previously granted restricted stock units vested and converted into common stock, increasing his direct holdings to 726,403 shares.

How many Aclaris Therapeutics (ACRS) shares does Anand Mehra hold after these transactions?

Following the June 5, 2026 vesting and conversion of 11,580 restricted stock units, Anand Mehra directly holds 726,403 shares of Aclaris Therapeutics common stock. This figure reflects his updated position after the non-cash equity compensation events reported in the Form 4.

What stock option grant did Anand Mehra receive from Aclaris Therapeutics (ACRS)?

On June 4, 2026, Anand Mehra received a stock option covering 42,350 shares of Aclaris Therapeutics common stock at an exercise price of $4.71 per share. The option vests in twelve equal monthly installments beginning on July 4, 2026, conditioned on his continuous service.

When will Anand Mehra’s new restricted stock units in Aclaris Therapeutics (ACRS) vest?

The 10,987 restricted stock units granted to Anand Mehra on June 4, 2026 are scheduled to vest in a single installment on June 4, 2027. Vesting is contingent on his continuous service under the company’s 2025 Equity Incentive Plan through that vesting date.

Were there any open-market buys or sells by Anand Mehra in Aclaris Therapeutics (ACRS)?

The reported transactions show no open-market purchases or sales. Activity consisted of equity awards and the exercise of previously granted restricted stock units into common shares, all at a transaction price of $0.00 per share, reflecting non-cash compensation events.

What triggered the 11,580-share increase in Anand Mehra’s Aclaris Therapeutics (ACRS) holdings?

The 11,580-share increase came from vesting of previously granted restricted stock units. On June 5, 2026, 11,580 restricted stock units vested and were converted into an equal number of common shares, as described in the footnote that states these units vested on that date.